Clinical characteristics and severity classification in Mixed Connective Tissue Disease: a nationwide retrospective study

OBJECTIVES: To characterize clinical manifestations, major organ involvement, real-world treatment patterns, and factors associated with severity classification in Japanese patients with mixed connective tissue disease (MCTD), aiming to clarify its heterogeneous clinical spectrum. METHODS: This nationwide retrospective multicenter study analyzed clinical data from 249 patients who strictly fulfilled the 2019 Japanese Ministry of Health, Labour and Welfare diagnostic criteria for MCTD, derived from an initial real-world registry of 311 clinically diagnosed patients. Clinical features, autoantibodies, and therapeutic regimens were summarized and compared between patients with severe versus non-severe disease. RESULTS: The cohort was 93.1% female (median onset age 40.6 years). Common findings, specifically Raynaud's phenomenon and/or swelling of the fingers or dorsum of the hands, were present in 100%. Phenotypically, an overlap of systemic lupus erythematosus (SLE)-like and systemic sclerosis (SSc)-like features was most frequent (56.0%), while 32.0% had manifestations across all three phenotypic domains (SLE-, SSc-, and IIM-like). Major organ involvement occurred in 32.9% of patients, including pulmonary arterial hypertension in 12.8%. Approximately 28.7% of evaluable patients were classified as severe. Off-scale-high anti-U1-RNP antibody status was not associated with severity classification (p = 0.492) or with broad phenotypic categories. Glucocorticoids and immunosuppressive agents were used in 66.7% and 56.5% of the patients, respectively. CONCLUSIONS: Mixed connective tissue disease exhibits marked clinical heterogeneity. Severity classification was not associated with off-scale-high anti-U1-RNP antibody status or broad phenotypic categories. These findings support rigorous cardiopulmonary screening and management tailored to the dominant clinical phenotype.

Authors

Institutions

Publication Details

Journal
Lara D. Veeken
Published
2026-10-15
DOI
https://doi.org/10.1093/rheumatology/keag577
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical characteristics and severity classification in Mixed Connective Tissue Disease: a nationwide retrospective study

Hidehiko Narazaki, Yuta Yamashita, Michihito Kono, Shirai Yuichiro et al.
Lara D. Veeken
Systemic Sclerosis and Related Diseases
article

Clinical characteristics and severity classification in Mixed Connective Tissue Disease: a nationwide retrospective study

Hidehiko Narazaki, Yuta Yamashita, Michihito Kono, Shirai Yuichiro, Hidekata Yasuoka, Yujiro Tanabe, Takehisa Ogura, Hideto Kameda, Yurie Sato-Kanda, Ran Nakashima, Satoshi Kubo, Keishi Fujio, Yumi Tsuchida, Shingo Nakayamada, Masataka Kuwana, Koichiro Ohmura, Yoshinao Muro, Takao Fujii, Shintaro Hirata, Tatsuya Atsumi, Konomi Akamatsu, Hisanori Hasegawa, Yoshiya Tanaka, Takashi Kato, Shusaku Fukaya
article en

Abstract

OBJECTIVES: To characterize clinical manifestations, major organ involvement, real-world treatment patterns, and factors associated with severity classification in Japanese patients with mixed connective tissue disease (MCTD), aiming to clarify its heterogeneous clinical spectrum. METHODS: This nationwide retrospective multicenter study analyzed clinical data from 249 patients who strictly fulfilled the 2019 Japanese Ministry of Health, Labour and Welfare diagnostic criteria for MCTD, derived from an initial real-world registry of 311 clinically diagnosed patients. Clinical features, autoantibodies, and therapeutic regimens were summarized and compared between patients with severe versus non-severe disease. RESULTS: The cohort was 93.1% female (median onset age 40.6 years). Common findings, specifically Raynaud's phenomenon and/or swelling of the fingers or dorsum of the hands, were present in 100%. Phenotypically, an overlap of systemic lupus erythematosus (SLE)-like and systemic sclerosis (SSc)-like features was most frequent (56.0%), while 32.0% had manifestations across all three phenotypic domains (SLE-, SSc-, and IIM-like). Major organ involvement occurred in 32.9% of patients, including pulmonary arterial hypertension in 12.8%. Approximately 28.7% of evaluable patients were classified as severe. Off-scale-high anti-U1-RNP antibody status was not associated with severity classification (p = 0.492) or with broad phenotypic categories. Glucocorticoids and immunosuppressive agents were used in 66.7% and 56.5% of the patients, respectively. CONCLUSIONS: Mixed connective tissue disease exhibits marked clinical heterogeneity. Severity classification was not associated with off-scale-high anti-U1-RNP antibody status or broad phenotypic categories. These findings support rigorous cardiopulmonary screening and management tailored to the dominant clinical phenotype.

Lara D. Veeken
Hiroshima University (JP), Toho University (JP), Fujita Health University (JP), University of Occupational and Environmental Health Japan (JP), Wakayama Medical University (JP), Sapporo University (JP), Hokkaido University (JP), Kyoto University (JP), ENT and Allergy (US), Hiroshima University Hospital (JP), Hokkaido University Hospital (JP), Office of International Affairs (US), Nippon Medical School Hospital (JP), Kobe City Medical Center General Hospital (JP), Nagoya University (JP), Nippon Medical School (JP)
Good health and well-being
Openalex Percentile: Top 13%
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.